Holen Sie sich die Stockscreener-App
9.52
2.26%
0.21
Handel nachbörslich:
9.61
0.09
+0.95%
Schlusskurs vom Vortag:
$9.31
Offen:
$9.19
24-Stunden-Volumen:
1.76M
Relative Volume:
0.79
Marktkapitalisierung:
$1.45B
Einnahmen:
$177.28M
Nettoeinkommen (Verlust:
$-195.24M
KGV:
-7.1045
EPS:
-1.34
Netto-Cashflow:
$-114.54M
1W Leistung:
+6.61%
1M Leistung:
+25.10%
6M Leistung:
+60.27%
1J Leistung:
+163.71%
1-Tages-Spanne:
$9.0701
$9.61
1-Wochen-Bereich:
$8.965
$9.685
52-Wochen-Spanne:
$2.99
$10.28
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
9.52 | 1.36B | 177.28M | -195.24M | -114.54M | -1.34 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at Key Conferences | ADPT Stock News - GuruFocus
Adaptive Biotechnologies’ MRD test featured in cancer studies - Investing.com
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
BNP Paribas Financial Markets Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock - Investing.com
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Janus Henderson Group PLC Buys Shares of 46,900 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Catherine Wood Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus
Northern Trust Corp Acquires 130,449 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Jane Street Group LLC Sells 97,690 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Lowered by Price T Rowe Associates Inc. MD - Defense World
Does Adaptive Biotechnologies Corp (NASDAQ: ADPT) Still Look Hot This Week? - Stocksregister
16,457 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by First Trust Advisors LP - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? - Yahoo Finance
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Brokerages Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Price Target at $9.50 - Defense World
Trading Day Review: Adaptive Biotechnologies Corp (ADPT) Loses Momentum, Closing at 8.81 - DWinneX
MetLife Investment Management LLC Acquires 3,650 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (ADPT) Price Target Raised by Piper San - GuruFocus
Adaptive Biotechnologies (ADPT) Price Target Raised by Piper Sandler | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Reaches Analyst Target Price - Nasdaq
ADPT Price Target Increased to $13 by Piper Sandler | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $9.00 at Morgan Stanley - Defense World
Adaptive Biotechnologies (ADPT) Price Target Raised by Morgan St - GuruFocus
5 Analysts Assess Adaptive Biotechnologies: What You Need To Know - Benzinga
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Stock Forecast: Downside Of -42.28% By 2025 - Stocksregister
Adaptive Biotechnologies (ADPT) Price Target Raised by Morgan Stanley | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (ADPT) Price Target Increased by Morgan Stanley | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Position Lifted by Wells Fargo & Company MN - Defense World
Adaptive Biotechnologies Soars 120% In 9 MonthsCan The Momentum Continue? - RTTNews
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57 - Yahoo Finance
Adaptive Biotechnologies Lifts Forecasts And Sees Share Price Jump - Finimize
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 12-Month High Following Earnings Beat - Defense World
Decoding Adaptive Biotechnologies Corp (ADPT): A Strategic SWOT Insight - GuruFocus
Adaptive Biotechnologies stock soars on Q1 earnings beat By Investing.com - Investing.com Canada
Adaptive Biotechnologies stock soars on Q1 earnings beat - Investing.com
Adaptive Biotechnologies Corp (ADPT) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results - Benzinga
Adaptive Biotechnologies (ADPT): Goldman Sachs Raises Price Target | ADPT Stock News - GuruFocus
Adaptive Biotechnologies rises after quarterly sales beat - TradingView
Adaptive Biotechnologies (ADPT) Soars 34% on Strong Q1 Earnings - RagingBull
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
Adaptive Biotechnologies Corp (ADPT) Q1 2025 Earnings Call Highlights: Strong MRD Revenue ... - Yahoo Finance
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):